secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2026-06-01T12:51:21+00:00
Accession:  0001193125-26-249951
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones
--------------------------------------------------------------------------------

- $1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.
- Edgewise to focus on cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003).
- Upfront proceeds fully fund EDG-7500 development through potential approval.
- On track to report 12-week CIRRUS-HCM Part D data in Q2 2026.
- Transaction expected to close Q3 2026, subject to HSR and customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000119312526249951/0001193125-26-249951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000119312526249951/d24037d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer